Objectives: Because access to sleep recordings is limited, there is a need for new reliable diagnostic tools for pediatric obstructive sleep apnea-hypopnea syndrome (OSAHS) diagnosis. A score calculated from a 30 minutes-home sleep videotape recording has already been proposed in 1996 with interesting results. The main objective of this pilot study was to assess the reliability of a similar score applied to reference PSG video recordings and calculated on two different time windows (30 and 10 minutes). Methods: Sixteen children suspected of OSAHS, aged between two and ten years, underwent video recording during overnight PSG. Video analysis was made during the second complete sleep cycle. A 30-minute risk score (RS30) and a 10-minute risk score (RS10) were established by analyzing seven parameters. The RS30 and RS10 were correlated with clinical examination data, a sleep questionnaire, the obstructive-apnea-hypopnea index (OAHI) and the oxygen desaturation index (ODI) from synchronized PSG results. Results: There was a significant correlation between both the RS30 and RS10, the OAHI and ODI. A RS30 ≥ 6.09 was predictive of an OAHI ≥ 5 per hour with a sensitivity of 83% and a specificity of 90%. A RS10 ≥ 6.50 was predictive of an OAHI ≥ 5 per hour with a sensitivity of 67% and a specificity of 100%. Conclusion: A risk score based on PSG video recordings shows a good correlation with PSG results, confirming previous reports. Further work should focus on applying this risk score to home sleep video recordings for the diagnosis of pediatric OSAHS.

Aim: Infantile haemangioma (IH) is the most common benign tumour in children. Since 2014, propranolol has become the first-choice therapy and currently Hemangiol® is the only approved drug for complicated haemangioma. This post-marketing study reported the use of Hemangiol® for IH in paediatric practice. Method and Results: From January 2014 to November 2018, 94 children (median age 4 [0;21] months; 75% female) treated with Hemangiol® for proliferative IH were enrolled in the study. The systematic paediatric cardiology consultation never contraindicated beta-blockers. Two Hemangiol® initiation protocols were used: a conventional ambulatory 3-week titration phase protocol (N=76, 80.9%), and a rapid initiation protocol with a 48-hour dose escalation in conventional hospitalization for severe proliferative IH (N=18, 19.1%). In both protocols, the haemodynamic tolerance was good. The mean maintenance dose of Hemangiol® was 2.7±0.8 mg/kg/day, with a median treatment duration of 7 [1.5;19] months. Adverse events (AEs) have been found in 25 (26,6%) patients including 8 (8.5%) patients with serious AEs (uncontrolled bronchial hyperreactivity, N=5; serious hypoglycaemia, N=3). Some patients had one or more AEs, a total of 24 non-serious AEs was reported in 19 patients (sleep disturbances, N=9; respiratory disorders, N=5; digestive disorders, N=6). No cardiac adverse event was reported. Conclusion: This post-marketing surveillance drug study supports the good tolerance of Hemangiol® in children with IH. A rapid initiation protocol is of interest when treatment is urgent. The pre-therapeutic paediatric cardiology consultation should not be systematic but only indicated on specific patients. ClinicalTrials.gov: NCT 04105517.